FLGC vs. VNRX, KLRS, GANX, IFRX, STTK, VRCA, NRXP, APLT, OSTX, and ATRA
Should you be buying Flora Growth stock or one of its competitors? The main competitors of Flora Growth include VolitionRx (VNRX), Allovir (KLRS), Gain Therapeutics (GANX), InflaRx (IFRX), Shattuck Labs (STTK), Verrica Pharmaceuticals (VRCA), NRx Pharmaceuticals (NRXP), Applied Therapeutics (APLT), OS Therapies (OSTX), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.
Flora Growth vs. Its Competitors
Flora Growth (NASDAQ:FLGC) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Flora Growth has a net margin of -30.99% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Flora Growth's return on equity.
VolitionRx has lower revenue, but higher earnings than Flora Growth. VolitionRx is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.
Flora Growth has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Flora Growth currently has a consensus price target of $4.00, suggesting a potential upside of 438.79%. VolitionRx has a consensus price target of $3.50, suggesting a potential upside of 450.49%. Given VolitionRx's stronger consensus rating and higher possible upside, analysts plainly believe VolitionRx is more favorable than Flora Growth.
36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 12.6% of Flora Growth shares are owned by insiders. Comparatively, 10.4% of VolitionRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, VolitionRx had 3 more articles in the media than Flora Growth. MarketBeat recorded 5 mentions for VolitionRx and 2 mentions for Flora Growth. Flora Growth's average media sentiment score of 1.57 beat VolitionRx's score of 0.52 indicating that Flora Growth is being referred to more favorably in the media.
Flora Growth and VolitionRx both received 15 outperform votes by MarketBeat users. However, 60.00% of users gave Flora Growth an outperform vote while only 20.83% of users gave VolitionRx an outperform vote.
Summary
Flora Growth and VolitionRx tied by winning 9 of the 18 factors compared between the two stocks.
Get Flora Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Flora Growth Competitors List
Related Companies and Tools
This page (NASDAQ:FLGC) was last updated on 6/13/2025 by MarketBeat.com Staff
